drugset / Trial / NCT05317767

The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years.

NCT05317767

RandomizedParallel-groupDouble-blindDiagnostic

Summary

Comparative assessment of the tolerability, safety and immunogenicity of the Flu-M vaccine vs. the Ultrix® vaccine by single vaccination of children aged 6 to 17 years.

Timeline

Start
2020-02-10
Primary completion
2020-07-05
Completion
2020-09-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Flu-M Vaccine 0.5 ml Intramuscular
Comparator Ultrix Vaccine 0.5 ml Intramuscular

Indications